Deciphera Pharmaceuticals, Inc. Submits Form 15-12G SEC Filing – Learn More About the Company and Filing Here
In a recent SEC filing, Deciphera Pharmaceuticals, Inc. submitted a Form 15-12G. This filing is significant as it indicates that the company has voluntarily deregistered its common stock with the Securities and Exchange Commission. By deregistering, Deciphera Pharmaceuticals is no longer required to file certain reports with the SEC, reducing administrative burdens and costs associated with compliance.
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing precision kinase inhibitors to address the needs of cancer patients. The company’s lead drug candidate, Qinlock, has received FDA approval for the treatment of advanced gastrointestinal stromal tumors. For more information about Deciphera Pharmaceuticals and its innovative pipeline of oncology therapies, visit their official website at https://www.deciphera.com/.
Form 15-12G is a filing with the SEC used to terminate the registration of a class of securities under Section 12(g) of the Securities Exchange Act of 1934. Companies typically file Form 15-12G when they have fewer than a certain number of shareholders of record, allowing them to suspend their reporting obligations with the SEC.
Read More:
Deciphera Pharmaceuticals, Inc. Submits Form 15-12G to SEC
